Evidence map›Paper›PMID 40571775›Full record

SynthesisGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025

Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis.

Ali Tahmasebi, Nazanin Ebrahimiadib, Mohammadreza Niyousha, Narges Hassanpoor

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ali TahmasebiStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Nazanin EbrahimiadibDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, FL, USA.
Mohammadreza NiyoushaEye Research Center, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Abbasi street, Tabriz, 5154645395, Iran.
Narges HassanpoorEye Research Center, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Abbasi street, Tabriz, 5154645395, Iran. nargeshassanpoor@gmail.com.ORCID http://orcid.org/0000-0001-8296-0918

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess functional and anatomical results of switching to faricimab after prior anti-vascular endothelial growth factor (anti-VEGF) therapy with bevacizumab and/or ranibizumab and/or aflibercept in persistent diabetic macular edema (DME).

methodsWe performed a systematic search of literature across four primary electronic databases (PubMed, Embase, Web of Science, and Scopus) prior to January 2025 to find the articles on switching to faricimab in refractory DME. Therapeutic effect parameters, including mean change of best-corrected visual acuity (BCVA), central macular thickness (CMT) and injection intervals were extracted from baseline to different follow-up timelines.

resultsSix hundred twenty-nine eyes from 564 patients of fifteen studies, published between 2022 and January 2025, were included in this systematic review, all of which employed a retrospective cohort design. Most participants in the included studies had prior anti-VEGF therapies which were predominantly aflibercept, with fewer cases received ranibizumab and/or bevacizumab. Meta-analysis showed that BCVA improved significantly () in both 1 month and 3 to 12 months after switching. The pooled mean difference was - 0.03 (95%CI: -0.06 to -0.01, ) at 1 month post faricimab injection and - 0.05 (95% CI: -0.08 to -0.03, ) at 3-12 months. CMT also showed significant improvement after switching to faricimab in different follow up periods including even one month and 3-12 months after first faricimab injection. The pooled mean difference was - 54.69 and - 103.5 μm, respectively. Moreover, the pooled results from six studies indicate a significant prolongation in treatment intervals, with a mean difference of 1.53 weeks.

conclusionBased on this meta-analysis, switching to faricimab can be considered for patients with persistent DME and can lead to functional or anatomical improvement.

Indexed as

Diabetic RetinopathyDrug SubstitutionMacular EdemaVisual AcuityAngiogenesis InhibitorsAntibodies, BispecificBevacizumabHumansIntravitreal InjectionsMacula LuteaRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsTomography, Optical CoherenceVascular Endothelial Growth Factor AafliberceptAngiogenesis InhibitorsAntibodies, BispecificBevacizumabfaricimabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAfliberceptDiabetic macular edemaFaricimabMeta-analysisPersistent DMESystematic review

Identifiers

PMID40571775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.